May 21, 2019 / 10:30AM GMT
Unidentified Participant -
Thanks, Carina. Welcome to all the participants and welcome to the Thyrocare management, and thanks for giving us this opportunity of hosting the call. We have with us from the management side Dr. Velumani, who's the CEO; Dr. Sundararaju, the CFO; Mr. Sachin Salvi, VP, Finance; and Dr. Caesar Sengupta, VP, Operations. I request, Sachin Salvi, if you can take us through the quarter 4 numbers, and after that, Dr. Velumani can guide us on the overall strategic perspective of the business. Over to you, Sachin.
Sachin Salvi - Thyrocare Technologies Limited - General Manager of Finance
Sure. Thank you. Good evening, everyone. So Thyrocare Technologies Limited has disclosed its financial performance for the quarter and financial year ended 31st March 2019 on 18th of May 2019. Our annual consolidated revenue of INR 402.91 crores has grown by about 13%. Our EBITDA of about INR 160.37 crores has grown by about 9%. We are maintaining our EBITDA margin at a consolidated level of 40%. Our stand-alone revenue, which is INR 370.28 crores has grown by about 12
Q4 2019 Thyrocare Technologies Ltd Earnings Call Transcript
Mar 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers